Skip to main content

Nephros Inc

NEPH
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001196298

In the last 90 days, Nephros Inc insiders filed 1 open-market purchase and 0 sales; 35 institutions reported holding it in 13F filings for Q3 2026, worth $9.54M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 19, 2026
$30.9M
Insider buysLast 90 days, $22.1K in total
1
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +2 vs. previous quarter
35
13F valueReported value at the end of Q3 2026
$9.54M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$18.8M
+32.7% year over year
Net income, FY2025
$1.19M
+1,513.5% year over year
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q3 FY2026
$5.62M
+18.0% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
11.9K
Shares sold short
Change
−3.53K
−22.9% vs. previous
Days to cover
1.00
At average daily volume

Superinvestors holding NEPH, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding NEPH at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Nephros Inc insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 18, 2026 (view filing)4:57 PM ETNov 16-172 daysAmron Arthur HDirectorPPurchase+7.50K$2.94+$22.1K+4.6%169.6K after2 lots
May 30, 2024 (view filing)May 28-302 daysAmron Arthur HDirectorPPurchase+5.00K$2.23+$11.2K+5.1%103.5K after2 lots
May 16, 2024 (view filing)May 16Same dayBanks Robert R. Jr.President and CEOPPurchase+50.0K$2.24+$112.0K+250.0%70.0K after
Mar 14, 2024 (view filing)Mar 122 daysAmron Arthur HDirectorPPurchase+7.00K$2.45+$17.1KNew position7.00K after
Dec 11, 2023 (view filing)Dec 74 daysBanks Robert R. Jr.President and CEOPPurchase+18.0K$2.20+$39.6K+900.0%20.0K after
Aug 15, 2023 (view filing)Aug 14-151 dayBanks Robert R. Jr.President and CEOPPurchase+2.00K$1.68+$3.36KNew position2.00K after2 lots
Aug 23, 2021 (view filing)Aug 203 daysLobo Wesley S.Chief Marketing OfficerPPurchase+1.00K$7.92+$7.92K+2.5%41.6K after
Aug 19, 2021 (view filing)Aug 181 dayGwydir TomDirectorPPurchase+5.00K$7.64+$38.2K+82.9%11.0K after
Aug 18, 2021 (view filing)Aug 17-181 dayAstor AndrewPresident & CEOPPurchase+5.00K$7.72+$38.6K+6.9%78.0K after2 lots

Top 10 13F holders, Q3 2026

See all 35 holders

The largest institutional positions in Nephros Inc at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding NEPH in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Topline Capital Management, LLC535,698$1.99M0.44%00.0%Unchanged
Massachusetts Institute of Technology346,813$1.29M0.19%+346,813New
Wexford Capital LP231,068$829.3K0.11%−3,369,484−93.6%Reduced
Vanguard Capital Management LLC198,643$737.0K0.00%00.0%Unchanged
Johns Hopkins University187,857$696.9K0.05%+187,857New
Meritage Group LP173,407$643.3K0.02%+173,407New
Morgan Stanley123,915$459.7K0.00%−5,000−3.9%Reduced
Blackstone Group Inc.115,605$428.9K0.00%+115,605New
Bard Associates Inc115,528$428.6K0.10%−2,475−2.1%Reduced
Renaissance Technologies LLC71,100$263.8K0.00%−6,404−8.3%Reduced

Holders of 5% or more of NEPH

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Nephros Inc.

Largest holders of NEPH from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Topline Capital Management, LLC13G/A6.40%705.7K shares+0.80 ppfrom 5.60%Nov 14, 20252 filingsNov 16, 2026SEC
Davidson Charles E13G5.68%616.9K sharesNewSep 16, 20261 filingSep 16, 2026SEC